Skip to content
PICO PortalSearch builder

From a question

What factors are associated with recurrence, progression, survival, BCG unresponsiveness, or cystectomy in adults with high-risk NMIBC?

DoneStarted Oct 28, 2026, 18:54 UTCFinished Oct 28, 2026, 18:55 UTC

Stages

  1. Finding the known studies(done)
  2. Drafting(done)
  3. Checking MeSH(done)
  4. Counting in PubMed(done)
  5. Checking known studies(done)
  6. Comparing with the reference(done)
  7. Run Search(done)
  8. Saving(done)
Run log (26)
  1. Finding the known studies: No known studies were given
  2. Drafting: Drafting concepts and terms
  3. Checking MeSH: Checking every MeSH heading, Supplementary Concept and publication type against NLM
  4. Counting in PubMed: Running 19 lines on PubMed
  5. Line 4: 54,049 records
  6. Line 2: 85,737 records
  7. Line 3: 103,654 records
  8. Line 5: 85,031 records
  9. Line 6: 1,499 records
  10. Line 7: 108,908 records
  11. Line 9: 531,268 records
  12. Line 10: 5,161,509 records
  13. Line 11: 6,455,728 records
  14. Line 1: 76,110 records
  15. Line 12: 1,007,392 records
  16. Line 14: 4,250,666 records
  17. Line 16: 4,884,955 records
  18. Line 15: 7,885 records
  19. Line 8: 2,283,845 records
  20. Line 18: 6,907 records
  21. Line 19: 593,438 records
  22. Line 13: 3,941,252 records
  23. Line 17: 7,458 records
  24. Run Search: Fetching the first 20 records
  25. Saving: Saving the run
  26. Finished.

Final count (line 18)

6,907

Open in PubMed (opens in a new tab)
Query as run (2,029 characters)(((("Urinary Bladder Neoplasms"[Mesh] OR "Carcinoma, Transitional Cell"[Mesh]) OR ("bladder cancer*"[tiab] OR "bladder tumor*"[tiab] OR "bladder tumour*"[tiab] OR "bladder neoplasm*"[tiab] OR "bladder carcinoma*"[tiab] OR "urothelial carcinoma*"[tiab] OR "urothelial cancer*"[tiab] OR "transitional cell carcinoma*"[tiab] OR NMIBC[tiab])) AND (("Carcinoma in Situ"[Mesh] OR "BCG Vaccine"[Mesh] OR "Administration, Intravesical"[Mesh]) OR ("non-muscle invasive"[tiab] OR "nonmuscle invasive"[tiab] OR NMIBC[tiab] OR "superficial bladder"[tiab:~2] OR "carcinoma in situ"[tiab] OR T1G3[tiab] OR pT1[tiab] OR "stage T1"[tiab] OR "T1 bladder"[tiab:~2] OR BCG[tiab] OR "Calmette-Guerin"[tiab] OR intravesical[tiab] OR TURBT[tiab] OR "transurethral resection"[tiab]) OR ("non-muscle invasive"[ot])) AND (("Prognosis"[Mesh:NoExp] OR "Risk Factors"[Mesh] OR "Risk Assessment"[Mesh] OR "Biomarkers, Tumor"[Mesh] OR "Nomograms"[Mesh] OR "Proportional Hazards Models"[Mesh] OR "Multivariate Analysis"[Mesh]) OR ("associated with"[ti]) OR (prognos*[tiab] OR predict*[tiab] OR "risk factor*"[tiab] OR "hazard ratio*"[tiab] OR "odds ratio*"[tiab] OR multivariate[tiab] OR multivariable[tiab] OR nomogram*[tiab] OR "risk stratification"[tiab] OR "risk score*"[tiab] OR "risk group*"[tiab] OR biomarker*[tiab])) AND (("Neoplasm Recurrence, Local"[Mesh] OR "Recurrence"[Mesh:NoExp] OR "Disease Progression"[Mesh] OR "Survival Analysis"[Mesh] OR "Progression-Free Survival"[Mesh] OR "Cystectomy"[Mesh] OR "Treatment Failure"[Mesh] OR "Drug Resistance, Neoplasm"[Mesh]) OR (recurren*[tiab] OR relapse*[tiab] OR progression[tiab] OR "muscle invasion"[tiab] OR upstaging[tiab] OR survival[tiab] OR mortality[tiab] OR cystectom*[tiab] OR "BCG unresponsive*"[tiab] OR "BCG refractory"[tiab] OR "BCG failure*"[tiab] OR "BCG relapsing"[tiab] OR "treatment failure"[tiab]))) NOT ("Comment"[Publication Type] OR "Editorial"[Publication Type] OR "Letter"[Publication Type] OR "Case Reports"[Publication Type] OR "Preprint"[Publication Type])) AND english[la]

Known studies

No known studies were given, so recall was not checked.

Only studies the model never saw are counted. Finding known studies does not prove the search is complete.

Reference strategy

No reference strategy was given.

Search lines

Vocabulary terms are marked ✓︎ valid, ↪︎ mapped to the preferred heading, ✗︎ not found, ⚠︎ not checked.
Numbered search lines with their PubMed counts
No.SearchResults
1

Bladder or urothelial cancer

"Urinary Bladder Neoplasms"[Mesh] (MeSH heading valid: D001749) OR "Carcinoma, Transitional Cell"[Mesh] (MeSH heading valid: D002295)		76,110
2

Bladder or urothelial cancer

"bladder cancer*"[tiab] OR "bladder tumor*"[tiab] OR "bladder tumour*"[tiab] OR "bladder neoplasm*"[tiab] OR "bladder carcinoma*"[tiab] OR "urothelial carcinoma*"[tiab] OR "urothelial cancer*"[tiab] OR "transitional cell carcinoma*"[tiab] OR NMIBC[tiab]		85,737
3

Bladder or urothelial cancer · block

1 OR 2		103,654
4

Non-muscle-invasive disease

"Carcinoma in Situ"[Mesh] (MeSH heading valid: D002278) OR "BCG Vaccine"[Mesh] (MeSH heading valid: D001500) OR "Administration, Intravesical"[Mesh] (MeSH heading valid: D000283)		54,049
5

Non-muscle-invasive disease

"non-muscle invasive"[tiab] OR "nonmuscle invasive"[tiab] OR NMIBC[tiab] OR "superficial bladder"[tiab:~2] OR "carcinoma in situ"[tiab] OR T1G3[tiab] OR pT1[tiab] OR "stage T1"[tiab] OR "T1 bladder"[tiab:~2] OR BCG[tiab] OR "Calmette-Guerin"[tiab] OR intravesical[tiab] OR TURBT[tiab] OR "transurethral resection"[tiab]
  • Note: "non-muscle invasive"[ot] adds almost nothing to "non-muscle invasive"[tiab], which already searches the title, the abstract and the keywords.
85,031
6

Non-muscle-invasive disease

"non-muscle invasive"[ot]
  • Note: "non-muscle invasive"[ot] adds almost nothing to "non-muscle invasive"[tiab], which already searches the title, the abstract and the keywords.
1,499
7

Non-muscle-invasive disease · block

4 OR 5 OR 6		108,908
8

Prognostic or predictive factors

"Prognosis"[Mesh:NoExp] (MeSH heading valid: D011379) OR "Risk Factors"[Mesh] (MeSH heading valid: D012307) OR "Risk Assessment"[Mesh] (MeSH heading valid: D018570) OR "Biomarkers, Tumor"[Mesh] (MeSH heading valid: D014408) OR "Nomograms"[Mesh] (MeSH heading valid: D049451) OR "Proportional Hazards Models"[Mesh] (MeSH heading valid: D016016) OR "Multivariate Analysis"[Mesh] (MeSH heading valid: D015999)		2,283,845
9

Prognostic or predictive factors

"associated with"[ti]		531,268
10

Prognostic or predictive factors

prognos*[tiab] OR predict*[tiab] OR "risk factor*"[tiab] OR "hazard ratio*"[tiab] OR "odds ratio*"[tiab] OR multivariate[tiab] OR multivariable[tiab] OR nomogram*[tiab] OR "risk stratification"[tiab] OR "risk score*"[tiab] OR "risk group*"[tiab] OR biomarker*[tiab]		5,161,509
11

Prognostic or predictive factors · block

8 OR 9 OR 10		6,455,728
12

Recurrence, progression, survival, BCG unresponsiveness, cystectomy

"Neoplasm Recurrence, Local"[Mesh] (MeSH heading valid: D009364) OR "Recurrence"[Mesh:NoExp] (MeSH heading valid: D012008) OR "Disease Progression"[Mesh] (MeSH heading valid: D018450) OR "Survival Analysis"[Mesh] (MeSH heading valid: D016019) OR "Progression-Free Survival"[Mesh] (MeSH heading valid: D000077982) OR "Cystectomy"[Mesh] (MeSH heading valid: D015653) OR "Treatment Failure"[Mesh] (MeSH heading valid: D017211) OR "Drug Resistance, Neoplasm"[Mesh] (MeSH heading valid: D019008)		1,007,392
13

Recurrence, progression, survival, BCG unresponsiveness, cystectomy

recurren*[tiab] OR relapse*[tiab] OR progression[tiab] OR "muscle invasion"[tiab] OR upstaging[tiab] OR survival[tiab] OR mortality[tiab] OR cystectom*[tiab] OR "BCG unresponsive*"[tiab] OR "BCG refractory"[tiab] OR "BCG failure*"[tiab] OR "BCG relapsing"[tiab] OR "treatment failure"[tiab]		3,941,252
14

Recurrence, progression, survival, BCG unresponsiveness, cystectomy · block

12 OR 13		4,250,666
15

combined

3 AND 7 AND 11 AND 14		7,885
16

excluded

"Comment"[Publication Type] (publication type valid: D016420) OR "Editorial"[Publication Type] (publication type valid: D016421) OR "Letter"[Publication Type] (publication type valid: D016422) OR "Case Reports"[Publication Type] (publication type valid: D002363) OR "Preprint"[Publication Type] (publication type valid: D000076942)		4,884,955
17

exclusions removed

15 NOT 16		7,458
18Final

limits

17 AND english[la]		6,907
19

High-risk category

"high risk"[tiab] OR "high grade"[tiab] OR "highest risk"[tiab]		593,438

Issues

0 errors, 2 warnings, 1 notes
  • Warning: Language limit (english): it can remove relevant studies; report and justify it.
  • Warning: Publication types excluded with NOT (Comment, Editorial, Letter, Case Reports, Preprint): report and justify the exclusion.
  • Note: "non-muscle invasive"[ot] adds almost nothing to "non-muscle invasive"[tiab], which already searches the title, the abstract and the keywords.

First records

The first 20 of the final line's records, as PubMed sorts them.
  1. High Ubiquitin-like Protein 3 Expression Is Associated With Prolonged Recurrence-free Survival in Non-muscle-invasive Bladder Cancer. (PubMed, opens in a new tab)

    Sano A, Tamura K, Sakai Y et al. · Anticancer research · 2026 · PMID 42946445

  2. Elevated GANAB fuels PD-1/PD-L1 checkpoint-mediated immune escape by maintaining PD-L1 stability in bladder cancer. (PubMed, opens in a new tab)

    Jin X, Xu Y, Ling K et al. · Cellular signalling · 2026 · PMID 42927820

  3. Assessment of muscularis propria invasion in urothelial bladder carcinoma using continuous-time random walk and stretched-exponential models: Comparison with VI-RADS and apparent diffusion coefficient. (PubMed, opens in a new tab)

    Wu Y, Zhu X, Zhou X et al. · Experimental and therapeutic medicine · 2026 · PMID 42923499

  4. Research progress and clinical translation prospects of multiple urinary biomarkers in non-invasive diagnosis of urothelial carcinoma. (PubMed, opens in a new tab)

    Li S, Wang L, Gao B · Frontiers in oncology · 2026 · PMID 42923287

  5. Deciphering the clinical significance of Beclin-1 and Bcl-2 in urothelial carcinoma of bladder. (PubMed, opens in a new tab)

    Niharika, Tripathi S, Singhai A et al. · Indian journal of urology : IJU : journal of the Urological Society of India · 2026 · PMID 42910392

  6. Timing of FDA-Defined Adequate BCG Therapy and Oncologic Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer. (PubMed, opens in a new tab)

    Abou Chakra M, Myers AA, Duquesne I et al. · Urology practice · 2026 · PMID 42909595

  7. Population-specific molecular features and clinical significance of urinary tumor DNA mutations in Chinese patients with newly diagnosed non-muscle-invasive bladder cancer. (PubMed, opens in a new tab)

    Sun Z, Xie R, Pan J et al. · Frontiers in oncology · 2026 · PMID 42908741

  8. FGFR3 mRNA expression in urothelial bladder cancer: Associations with tumor phenotype without prognostic impact. (PubMed, opens in a new tab)

    Pakovski K, Markova M, Janchulev J et al. · Central European journal of urology · 2026 · PMID 42903929

  9. Reprogramming innate immune memory in bladder cancer: the proposed bone marrow-bladder axis and next-generation BCG-based immunotherapies. (PubMed, opens in a new tab)

    Yang M, Guo Y, Shen YZ et al. · Frontiers in immunology · 2026 · PMID 42903705

  10. Clinical Outcomes of Bladder-sparing Management Versus Early Radical Cystectomy in cT1 Micropapillary Bladder Cancer: A Systematic Review and Meta-analysis. (PubMed, opens in a new tab)

    Patel SR, Rauf M, Geng Y et al. · European urology oncology · 2026 · PMID 42901828

  11. Prognosis and tumor grading in bladder urothelial carcinomas with intratumoral grade heterogeneity. (PubMed, opens in a new tab)

    Alkan GV, Doğan K, Türk Alkan M et al. · Pathology oncology research : POR · 2026 · PMID 42898355

  12. Microbiome-urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation. (PubMed, opens in a new tab)

    Xu H, Li Z, Yang L et al. · iMetaOmics · 2026 · PMID 42891336

  13. NEITHER study: NICE versus EAU inconsistent triage, expenses and reliability in non-high-risk non-muscle invasive bladder cancer surveillance. (PubMed, opens in a new tab)

    Ibrahim Y, Ribeiro L, Heelan M et al. · BJUI compass · 2026 · PMID 42889172

  14. Risk factors for recurrence after initial transurethral resection of bladder tumor in patients with non-muscle-invasive bladder cancer. (PubMed, opens in a new tab)

    Yuan F, Li X, Zhang J et al. · Frontiers in oncology · 2026 · PMID 42889117

  15. Enhanced detection of bladder cancer using machine learning analysis of routine urinary sediment data. (PubMed, opens in a new tab)

    Okuyama R, Horiuchi H, Nakamura M et al. · Clinical chemistry and laboratory medicine · 2026 · PMID 42885914

  16. Bladder cancer organoids in precision medicine: bridging basic science, clinical therapeutics and drug development. (PubMed, opens in a new tab)

    Zhong X, Wang G, Zhang H et al. · Cancer cell international · 2026 · PMID 42881413

  17. Diet quality and prognosis in patients with non-muscle invasive bladder cancer: the Be-Well Study. (PubMed, opens in a new tab)

    Ergas IJ, Zimbalist A, Haque R et al. · Urology · 2026 · PMID 42880421

  18. Contemporary Oncological and Patient-reported Outcomes of Intravesical Gemcitabine/Docetaxel in BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Multi-institutional Prospective Cohort Study. (PubMed, opens in a new tab)

    Tan YG, Dudinec J, Kamat AM et al. · European urology focus · 2026 · PMID 42869744

  19. Urinary Extracellular Vesicle-Associated EphA2 Predicts Intravesical Recurrence in Bladder Cancer. (PubMed, opens in a new tab)

    Hashimoto M, Tomiyama E, Inoki L et al. · International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42866931

  20. An interpretable LASSO-Boruta nomogram for non-muscle-invasive bladder cancer recurrence after intravesical instillation. (PubMed, opens in a new tab)

    Li B, Ji G, Wang W et al. · Translational andrology and urology · 2026 · PMID 42866795

Export

Strategy (.txt)PMIDs (.txt)MEDLINE (.txt)Provenance (.json)

The strategy file has the numbered lines with counts, the search date and the AI-use statement. MEDLINE holds the first 2,000 records. PMIDs and MEDLINE are fetched from PubMed when you download, so they reflect PubMed today.

Checking PubMed for the current list of PMIDs…

Objective and notes from the draft

To identify clinical, pathological, molecular and treatment-related factors associated with recurrence, progression, survival, BCG-unresponsive disease or cystectomy in adults with high-risk non-muscle-invasive bladder cancer (NMIBC).

  • NMIBC has no dedicated MeSH heading to rely on, so the condition is built from two required blocks: bladder or urothelial cancer, ANDed with non-muscle-invasive, BCG or intravesical terms. This excludes muscle-invasive-only studies while keeping NMIBC studies that do not use the abbreviation.
  • The high-risk block is optional. Many studies of high-risk disease describe it only as T1, high-grade, carcinoma in situ or BCG-treated, which the non-muscle-invasive block already covers. Add the high-risk block if the result set is too large.
  • Prognosis is not exploded, to avoid pulling in the very broad Treatment Outcome subtree.
  • The bare word predict* and the title phrase 'associated with' are included for sensitivity; check their line counts and drop them if they add too much noise.
  • The question does not restrict the age group of the population, so no adult filter is applied; nearly all NMIBC studies involve adults.

Edit the strategy

Changes are not searched until you recount. Each recount is saved as a new version.

Bladder or urothelial cancerCondition

103,654 records · 11 of 11 terms on · 3 suggestions off

  • MeSH valid: D001749AI

    "Urinary Bladder Neoplasms"[Mesh]

    Main heading for bladder cancer, under which NMIBC studies are indexed.

  • MeSH valid: D002295AI

    "Carcinoma, Transitional Cell"[Mesh]

    Histological heading for urothelial carcinoma, often given to NMIBC records.

  • TextAI

    "bladder cancer*"[tiab]

    Most common author wording for the disease.

    Fields to search for bladder cancer
  • TextAI

    "bladder tumor*"[tiab]

    American spelling variant for bladder tumours.

    Fields to search for bladder tumor
  • TextAI

    "bladder tumour*"[tiab]

    British spelling variant.

    Fields to search for bladder tumour
  • TextAI

    "bladder neoplasm*"[tiab]

    Entry-term wording of the heading.

    Fields to search for bladder neoplasm
  • TextAI

    "bladder carcinoma*"[tiab]

    Common synonym for bladder cancer.

    Fields to search for bladder carcinoma
  • TextAI

    "urothelial carcinoma*"[tiab]

    Histological name used for NMIBC.

    Fields to search for urothelial carcinoma
  • TextAI

    "urothelial cancer*"[tiab]

    Variant of urothelial carcinoma.

    Fields to search for urothelial cancer
  • TextAI

    "transitional cell carcinoma*"[tiab]

    Older histological name still used in older studies.

    Fields to search for transitional cell carcinoma
  • TextAI

    NMIBC[tiab]

    Standard abbreviation that sometimes stands alone in titles and keywords.

    Fields to search for NMIBC
Suggested MeSH entry terms (3, off)
  • TextEntry term

    "Cancer of Bladder"[tiab]

    Narrower concept "Urinary Bladder Cancer" under the MeSH heading "Urinary Bladder Neoplasms" (D001749)

    Fields to search for Cancer of Bladder
  • TextEntry term

    "Cancer of the Bladder"[tiab]

    Narrower concept "Urinary Bladder Cancer" under the MeSH heading "Urinary Bladder Neoplasms" (D001749)

    Fields to search for Cancer of the Bladder
  • TextEntry term

    "Malignant Tumor of Urinary Bladder"[tiab]

    Narrower concept "Urinary Bladder Cancer" under the MeSH heading "Urinary Bladder Neoplasms" (D001749)

    Fields to search for Malignant Tumor of Urinary Bladder
Fields to search

Non-muscle-invasive diseaseCondition

108,908 records · 17 of 17 terms on · 2 suggestions off

  • MeSH valid: D002278AI

    "Carcinoma in Situ"[Mesh]

    Carcinoma in situ is a defining high-risk NMIBC category.

  • MeSH valid: D001500AI

    "BCG Vaccine"[Mesh]

    Intravesical BCG is the standard treatment of high-risk NMIBC, so BCG-treated cohorts are this population.

  • MeSH valid: D000283AI

    "Administration, Intravesical"[Mesh]

    Intravesical therapy is used only in non-muscle-invasive disease.

  • TextAI

    "non-muscle invasive"[tiab]

    Core descriptor of the disease stage; the hyphen also matches the spaced form.

    Fields to search for non-muscle invasive
    • Note: "non-muscle invasive"[ot] adds almost nothing to "non-muscle invasive"[tiab], which already searches the title, the abstract and the keywords.
  • TextAI

    "nonmuscle invasive"[tiab]

    Joined spelling variant.

    Fields to search for nonmuscle invasive
  • TextAI

    NMIBC[tiab]

    Standard abbreviation for non-muscle-invasive bladder cancer.

    Fields to search for NMIBC
  • TextAI

    "superficial bladder"[tiab:~2]

    Older term for NMIBC (superficial bladder cancer or tumours).

    Fields to search for superficial bladder
  • TextAI

    "carcinoma in situ"[tiab]

    High-risk NMIBC subtype, often abbreviated CIS in abstracts.

    Fields to search for carcinoma in situ
  • TextAI

    T1G3[tiab]

    Classic label for high-risk T1 high-grade tumours.

    Fields to search for T1G3
  • TextAI

    pT1[tiab]

    Pathological stage label used for T1 disease.

    Fields to search for pT1
  • TextAI

    "stage T1"[tiab]

    Wording for T1 tumours, a high-risk NMIBC category.

    Fields to search for stage T1
  • TextAI

    "T1 bladder"[tiab:~2]

    Catches T1 bladder cancer or tumour phrasing.

    Fields to search for T1 bladder
  • TextAI

    BCG[tiab]

    Abbreviation for bacillus Calmette-Guerin, the standard adjuvant therapy.

    Fields to search for BCG
  • TextAI

    "Calmette-Guerin"[tiab]

    Spelled-out BCG name.

    Fields to search for Calmette-Guerin
  • TextAI

    intravesical[tiab]

    Intravesical therapy is specific to non-muscle-invasive disease.

    Fields to search for intravesical
  • TextAI

    TURBT[tiab]

    Abbreviation for transurethral resection of bladder tumour, the initial treatment of NMIBC.

    Fields to search for TURBT
  • TextAI

    "transurethral resection"[tiab]

    Initial treatment of NMIBC, used to describe the cohorts.

    Fields to search for transurethral resection
Suggested MeSH entry terms (2, off)
  • TextEntry term

    "Calmette's Vaccine"[tiab]

    Synonym of the MeSH heading "BCG Vaccine" (D001500)

    Fields to search for Calmette's Vaccine
  • TextEntry term

    "Bladder Drug Administration"[tiab]

    Synonym of the MeSH heading "Administration, Intravesical" (D000283)

    Fields to search for Bladder Drug Administration
Fields to search

High-risk categoryPopulation

593,438 records · 3 of 3 terms on

  • TextAI

    "high risk"[tiab]

    Risk-group label used for these cohorts; also matches very high risk.

    Fields to search for high risk
  • TextAI

    "high grade"[tiab]

    High-grade tumours define high-risk NMIBC.

    Fields to search for high grade
  • TextAI

    "highest risk"[tiab]

    Alternative risk-group wording.

    Fields to search for highest risk
Fields to search

Prognostic or predictive factorsExposure

6,455,728 records · 20 of 20 terms on · 19 suggestions off

  • MeSH valid: D011379AI

    "Prognosis"[Mesh:NoExp]

    Core heading for prognostic studies; not exploded to avoid the very broad Treatment Outcome subtree.

  • MeSH valid: D012307AI

    "Risk Factors"[Mesh]

    Indexes studies of factors associated with outcomes.

  • MeSH valid: D018570AI

    "Risk Assessment"[Mesh]

    Covers risk stratification and risk scoring tools.

  • MeSH valid: D014408AI

    "Biomarkers, Tumor"[Mesh]

    Molecular and tissue markers studied as prognostic factors.

  • MeSH valid: D049451AI

    "Nomograms"[Mesh]

    Prediction tools such as the EORTC and CUETO scoring models.

  • MeSH valid: D016016AI

    "Proportional Hazards Models"[Mesh]

    Cox models are the usual analysis in prognostic factor studies.

  • MeSH valid: D015999AI

    "Multivariate Analysis"[Mesh]

    Multivariable analysis identifies independent prognostic factors.

  • TextAI

    prognos*[tiab]

    Catches prognosis, prognostic and prognosticator.

    Fields to search for prognos
  • TextAI

    predict*[tiab]

    Catches predictor, predictive and prediction.

    Fields to search for predict
  • TextAI

    "risk factor*"[tiab]

    Standard wording for associated factors.

    Fields to search for risk factor
  • TextAI

    "hazard ratio*"[tiab]

    Reported effect measure in prognostic studies.

    Fields to search for hazard ratio
  • TextAI

    "odds ratio*"[tiab]

    Reported effect measure for binary outcomes such as cystectomy.

    Fields to search for odds ratio
  • TextAI

    multivariate[tiab]

    Signals adjusted analysis of factors.

    Fields to search for multivariate
  • TextAI

    multivariable[tiab]

    Variant of multivariate.

    Fields to search for multivariable
  • TextAI

    nomogram*[tiab]

    Prediction tools.

    Fields to search for nomogram
  • TextAI

    "risk stratification"[tiab]

    Wording for risk-group models.

    Fields to search for risk stratification
  • TextAI

    "risk score*"[tiab]

    Covers EORTC, CUETO and other scoring systems.

    Fields to search for risk score
  • TextAI

    "risk group*"[tiab]

    Wording for risk stratification categories.

    Fields to search for risk group
  • TextAI

    biomarker*[tiab]

    Molecular factors studied for prognosis.

    Fields to search for biomarker
  • TextAI

    "associated with"[ti]

    Titles of association studies often state the factor is associated with an outcome; restricted to title to limit noise.

    Fields to search for associated with
Suggested MeSH entry terms (19, off)
  • TextEntry term

    "Population at Risk"[tiab]

    Narrower concept under the MeSH heading "Risk Factors" (D012307)

    Fields to search for Population at Risk
  • TextEntry term

    "Health Correlates"[tiab]

    Narrower concept under the MeSH heading "Risk Factors" (D012307)

    Fields to search for Health Correlates
  • TextEntry term

    "Populations at Risk"[tiab]

    Narrower concept "Population at Risk" under the MeSH heading "Risk Factors" (D012307)

    Fields to search for Populations at Risk
  • TextEntry term

    "Health Risk Assessment"[tiab]

    Synonym of the MeSH heading "Risk Assessment" (D018570)

    Fields to search for Health Risk Assessment
  • TextEntry term

    "Benefit-Risk Assessment"[tiab]

    Narrower concept under the MeSH heading "Risk Assessment" (D018570)

    Fields to search for Benefit-Risk Assessment
  • TextEntry term

    "Risk-Benefit Assessment"[tiab]

    Narrower concept "Benefit-Risk Assessment" under the MeSH heading "Risk Assessment" (D018570)

    Fields to search for Risk-Benefit Assessment
  • TextEntry term

    "Carcinogen Markers"[tiab]

    Synonym of the MeSH heading "Biomarkers, Tumor" (D014408)

    Fields to search for Carcinogen Markers
  • TextEntry term

    "Biological Tumor Marker"[tiab]

    Synonym of the MeSH heading "Biomarkers, Tumor" (D014408)

    Fields to search for Biological Tumor Marker
  • TextEntry term

    "Tumor Metabolite Marker"[tiab]

    Synonym of the MeSH heading "Biomarkers, Tumor" (D014408)

    Fields to search for Tumor Metabolite Marker
  • TextEntry term

    "Biochemical Tumor Marker"[tiab]

    Synonym of the MeSH heading "Biomarkers, Tumor" (D014408)

    Fields to search for Biochemical Tumor Marker
  • TextEntry term

    "Biological Tumor Markers"[tiab]

    Synonym of the MeSH heading "Biomarkers, Tumor" (D014408)

    Fields to search for Biological Tumor Markers
  • TextEntry term

    "Biochemical Tumor Markers"[tiab]

    Synonym of the MeSH heading "Biomarkers, Tumor" (D014408)

    Fields to search for Biochemical Tumor Markers
  • TextEntry term

    "Partin Tables"[tiab]

    Narrower concept under the MeSH heading "Nomograms" (D049451)

    Fields to search for Partin Tables
  • TextEntry term

    "Proportional Hazard Model"[tiab]

    Synonym of the MeSH heading "Proportional Hazards Models" (D016016)

    Fields to search for Proportional Hazard Model
  • TextEntry term

    "Proportional Hazard Models"[tiab]

    Synonym of the MeSH heading "Proportional Hazards Models" (D016016)

    Fields to search for Proportional Hazard Models
  • TextEntry term

    "Proportional Hazards Model"[tiab]

    Synonym of the MeSH heading "Proportional Hazards Models" (D016016)

    Fields to search for Proportional Hazards Model
  • TextEntry term

    "Cox Proportional Hazards Models"[tiab]

    Narrower concept under the MeSH heading "Proportional Hazards Models" (D016016)

    Fields to search for Cox Proportional Hazards Models
  • TextEntry term

    "Cox Models"[tiab]

    Narrower concept under the MeSH heading "Proportional Hazards Models" (D016016)

    Fields to search for Cox Models
  • TextEntry term

    "Cox Proportional Hazards Model"[tiab]

    Narrower concept "Cox Proportional Hazards Models" under the MeSH heading "Proportional Hazards Models" (D016016)

    Fields to search for Cox Proportional Hazards Model
Fields to search

Recurrence, progression, survival, BCG unresponsiveness, cystectomyOutcome

4,250,666 records · 21 of 21 terms on · 4 suggestions off

  • MeSH valid: D009364AI

    "Neoplasm Recurrence, Local"[Mesh]

    Heading for tumour recurrence.

  • MeSH valid: D012008AI

    "Recurrence"[Mesh:NoExp]

    General recurrence heading sometimes used instead.

  • MeSH valid: D018450AI

    "Disease Progression"[Mesh]

    Heading for progression to muscle-invasive disease.

  • MeSH valid: D016019AI

    "Survival Analysis"[Mesh]

    Covers disease-free survival, Kaplan-Meier and survival rates.

  • MeSH valid: D000077982AI

    "Progression-Free Survival"[Mesh]

    Specific survival outcome heading.

  • MeSH valid: D015653AI

    "Cystectomy"[Mesh]

    Cystectomy is a named outcome of the review.

  • MeSH valid: D017211AI

    "Treatment Failure"[Mesh]

    Indexes BCG failure and unresponsive disease.

  • MeSH valid: D019008AI

    "Drug Resistance, Neoplasm"[Mesh]

    Can be used for BCG-refractory disease.

  • TextAI

    recurren*[tiab]

    Catches recurrence, recurrent and recurrence-free.

    Fields to search for recurren
  • TextAI

    relapse*[tiab]

    Synonym for recurrence.

    Fields to search for relapse
  • TextAI

    progression[tiab]

    Progression to muscle-invasive or metastatic disease.

    Fields to search for progression
  • TextAI

    "muscle invasion"[tiab]

    Description of progression.

    Fields to search for muscle invasion
  • TextAI

    upstaging[tiab]

    Related progression outcome.

    Fields to search for upstaging
  • TextAI

    survival[tiab]

    Overall, cancer-specific and progression-free survival.

    Fields to search for survival
  • TextAI

    mortality[tiab]

    Death outcomes.

    Fields to search for mortality
  • TextAI

    cystectom*[tiab]

    Catches cystectomy and cystectomies, including radical and early cystectomy.

    Fields to search for cystectom
  • TextAI

    "BCG unresponsive*"[tiab]

    Catches BCG-unresponsive and BCG-unresponsiveness.

    Fields to search for BCG unresponsive
  • TextAI

    "BCG refractory"[tiab]

    Related BCG failure category.

    Fields to search for BCG refractory
  • TextAI

    "BCG failure*"[tiab]

    General term for failure of BCG therapy.

    Fields to search for BCG failure
  • TextAI

    "BCG relapsing"[tiab]

    BCG failure subtype.

    Fields to search for BCG relapsing
  • TextAI

    "treatment failure"[tiab]

    General failure wording.

    Fields to search for treatment failure
Suggested MeSH entry terms (4, off)
  • TextEntry term

    Recrudescence[tiab]

    Narrower concept under the MeSH heading "Recurrence" (D012008)

    Fields to search for Recrudescence
  • TextEntry term

    "Neoplasm Drug Resistance"[tiab]

    Synonym of the MeSH heading "Drug Resistance, Neoplasm" (D019008)

    Fields to search for Neoplasm Drug Resistance
  • TextEntry term

    "Antineoplastic Drug Resistance"[tiab]

    Synonym of the MeSH heading "Drug Resistance, Neoplasm" (D019008)

    Fields to search for Antineoplastic Drug Resistance
  • TextEntry term

    "Antineoplastic Agent Resistance"[tiab]

    Synonym of the MeSH heading "Drug Resistance, Neoplasm" (D019008)

    Fields to search for Antineoplastic Agent Resistance
Fields to search

Limits

Publication types to exclude

Each one is checked against MeSH publication types before it is added.

  • Comment
  • Editorial
  • Letter
  • Case Reports
  • Preprint

No changes.